Tome Biosciences is the programmable gene insertion company. Using CRISPR, our technologies allow us to insert any genetic sequence of any size at any location into any genome. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and genome engineering.

Tome Biosciences

Domain Not Resolving

SSL by Default

HSTS

DNSSEC

nginx

Microsoft Exchange Online

Office 365 Mail

Google

Google Cloud

SVP, Business Development

Hilary Eaton

SVP, Intellectual Property

Konstantinos Andrikopoulos

Senior Director, Program and Alliance Management

Adrianne Monsef

Director, Cell Therapy

Chong Luo

Director of Genomics

Dane Hazelbaker

Senior Director of Genomics

Daniel O'Connell

Operations

Jason Gatlin

Associate Director

Jesse Cochrane

Business Management

Joel Gaston

Senior Director of Facilities

John Platt

Alan Crane

Daniel Lynch

Jay Markowitz

Jorge Conde

Rahul Kakkar

President & CEO

Northeastern US Companies With More Than 10 Employees (Top 10K)

Massachusetts Companies With Fewer Than 1000 Employees (Top 10K)

Massachusetts Companies With More Than 10 Employees (Top 10K)

East Coast Companies With Fewer Than 1000 Employees (Top 10K)

Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.  Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome.

Series A - Tome Biosciences

Watertown

Massachusetts

United States

North America

Gene editing sector investment struggles: What’s driving the slowdown?

The Crunchbase Tech Layoffs Tracker

Tome Biosciences files notice to lay off virtually entire staff

Gene insertion startup Tome Biosciences stops lab work as CEO shifts focus to deal talks

FUJIFILM Cellular Dynamics, Inc’s Post

FUJIFILM Cellular Dynamics, Inc on LinkedIn: #ipsc #stemcells #celltherapies

Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT

Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT

A technology for integrating large DNA sequences (>1,000 base pairs) into the genome at user-defined locations using a proprietary integrase.

A technology for integrating small DNA sequences (1-100s of base pairs) into the genome at user-defined locations using a DNA ligase.

A gene therapy approach to treat phenylketonuria (PKU) by inserting a healthy copy of the PAH gene into its natural genomic location.

A gene therapy approach to treat atherosclerotic cardiovascular disease (ASCVD) by increasing the expression of the ApoA-1 gene.

A gene therapy approach to treat homocystinuria (HCU) by inserting a healthy copy of the CBS gene into its natural or a defined genomic location.

A gene therapy approach to treat hereditary hemochromatosis by editing the HFE gene to address iron overload.

Tome Biosciences is a biotechnology company that develops programmable gene insertion technology using CRISPR, allowing the insertion of any genetic sequence of any size at any location into any genome. The company focuses on cell and integrative gene therapies for patient care.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	b4fc50fa
crunchbase profile	general	Nov 22, 2024 9:05 AM	ceeca7e7
li profile	general	Feb 2, 2024 11:22 PM	43dfd202
translate crunchbase fundingrounds	general	Nov 22, 2024 1:53 PM	3d9e5f8c
peers	general	Feb 2, 2024 11:23 PM	bfb6c5e3
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIO:TOME

Tome Biosciences